Ferronova完成了测试其铁质追踪器的试验,以帮助外科医生发现在胃部和食道癌患者中传播的癌症。 Ferronova finishes trial testing its iron-based tracer to help surgeons detect cancer spread in stomach and esophageal cancer patients.

Ferronova完成了其FerroTrace技术临床试验的注册,使用超单磁铁氧化铁纳米粒子帮助外科医生在胃癌和眼科癌症手术期间识别受癌症影响的淋巴结。 Ferronova has completed enrolment in a clinical trial testing its FerroTrace technology, using super-paramagnetic iron oxide nanoparticles to help surgeons identify cancer-affected lymph nodes during gastric and oesophageal cancer surgery. 该审判在澳大利亚五家医院进行,涉及62名病人,在化疗或放射治疗之前首先使用追踪器。 The trial, conducted across five Australian hospitals and involving 62 patients, is the first to use the tracer before chemotherapy or radiotherapy. 预计到2026年7月将取得结果,可以改进外科精确度,减少癌症复发,并提高这些侵袭性癌症的存活率。 Results are expected by July 2026 and could improve surgical precision, reduce cancer recurrence, and enhance survival rates for these aggressive cancers. 该公司还任命病人律师Aki Smith参加其科学咨询委员会,并继续得到政府赠款和私人投资者的支持。 The company also appointed patient advocate Aki Smith to its scientific advisory board and continues to receive support from government grants and private investors.